Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473799 | 0.92 | HPGD (0.56) | CA1CA2CA9ALDH1A1NAMPT | |
| SCHEMBL1679566 | 0.85 | ALDH1A1 (0.45) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL15648726 | 0.85 | CA1 (0.61) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL16183487 | 0.85 | CA1 (0.61) | CA1CA2CA9ALDH1A1NAMPT | |
| SCHEMBL15739681 | 0.82 | CA1 (0.49) | CA1CA2CA9ALDH1A1HDAC4 | |
| SCHEMBL15551680 | 0.82 | CA1 (0.59) | CA1CA2CA9ALDH1A1NAMPT | |
| SCHEMBL31144570 | 0.82 | POLB (0.57) | CA1CA2CA9NAMPTSMN1; SMN2 | |
| SCHEMBL14242308 | 0.81 | CA9 (0.60) | CA1CA2CA9 | |
| SCHEMBL21911540 | 0.81 | USP30 (0.49) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL2848982 | 0.81 | HTT (0.48) | CA1CA2CA9ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978751-B1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-26 | — | — | US | disclosed |
| EP-2766347-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2978751-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-02-03 | — | — | EP | disclosed |
| US-9079929-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100048576-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008030795-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARDS OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | ABL1, LCK, SRC | CA1 3713/4885CA2 2250/4885CA9 2706/4885 |
| US-20100048576-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CA1 4022/4885CA2 990/4885CA9 2915/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | CA1 4700/4885CA2 4439/4885CA9 4419/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | CA1 4022/4885CA2 990/4885CA9 2915/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | CA1 4700/4885CA2 4439/4885CA9 4419/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | CA1 3677/4885CA2 1960/4885CA9 4386/4885 |
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | TFPI2, TFPI, F12 | CA1 1769/4885CA2 1459/4885CA9 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.